We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Brain Biomarkers Predict Alzheimer's Disease Risk and Progression

By LabMedica International staff writers
Posted on 26 Aug 2019
A cluster of genes has been identified that modulates the activity of TREM2 (Triggering receptor expressed on myeloid cells 2), a protein biomarker for risk and progression of Alzheimer’s disease (AD).

Soluble TREM2 (sTREM2) has been detected in human cerebrospinal fluid (CSF), where it was found to be elevated in CSF of patients with multiple sclerosis and other inflammatory neurological conditions in comparison to patients without inflammatory neurologic disorders. More...
Moreover, while genetic variants in TREM2 are associated with AD risk and change with AD progression, genetic modifiers of CSF sTREM2 remain unknown.

In order to better understand the role of sTREM2 in AD, investigators at Washington University School of Medicine (St. Louis, MO, USA) performed a genome-wide association study (GWAS) to identify genetic modifiers of sTREM2 in samples of CSF provided by the Alzheimer’s Disease Neuroimaging Initiative. For this study, the investigators measured sTREM2 levels in the cerebrospinal fluid of 813 older adults, most of whom were ages 55 to 90. Of those subjects, 172 had Alzheimer's disease, 169 were cognitively normal, and 183 had early mild cognitive impairment.

Results revealed that common variants in the membrane-spanning 4-domains subfamily A (MS4A) gene region were associated with CSF sTREM2 concentrations. The variants associated with increased CSF sTREM2 concentrations were associated with reduced AD risk and delayed age at onset of disease. A single-nucleotide polymorphism (SNP) modified expression of the MS4A4A and MS4A6A genes in multiple tissues, suggesting that one or both of these genes were important for modulating sTREM2 production.

The investigators used human macrophages as a proxy for brain microglia to show that MS4A4A and TREM2 co-localized on lipid rafts at the plasma membrane, that sTREM2 increased with MS4A4A overexpression, and that silencing of MS4A4A reduced sTREM2 production. These genetic, molecular, and cellular findings suggested that MS4A4A was a modulator of sTREM2.

"We observed TREM2 risk variants more often in people who had Alzheimer's or were mildly cognitively impaired, compared with those who were cognitively normal," said contributing author Dr. Celeste Karch, assistant professor of psychiatry at Washington University School of Medicine. "It turns out that about 30% of the population in the study had variations in the MS4A4A gene that appear to affect their risk for developing Alzheimer's disease. Some variants protected people from Alzheimer's or made them more resilient while others increased their risk."

The study was published in the August 14, 2019, online edition of the journal Science Translational Medicine.

Related Links:
Washington University School of Medicine
Alzheimer’s Disease Neuroimaging Initiative


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.